Oncogenic ATK signaling can be activated by the changes of cell membrane contents, such as increased lipid rafts, and further contributes to hyperactivation of mTORC1 and mTORC2 [8], and as a consequence, the activation of the AKT-mTOR pathway can contribute to the enzalutamide resistance of prostate cancer [13]. The gene discussed is AKT1; the disease is prostate carcinoma.